Roche is making a deeper play in obesity by extending its China deal streak with a $1.2B pact for an ALK7 RNA interference program from Rona Therapeutics, targeting a genetically validated driver of visceral fat. The agreement adds to Roche’s growing bets on RNAi medicines for cardiometabolic indications. The ALK7 target has attracted other industry attention, including GSK and Arrowhead, underscoring competitive interest in pathway biology beyond appetite-centric GLP-1 strategies. For Roche, the move reinforces a strategy of pairing validated targets with platform-driven therapeutics as obesity drug competition intensifies. The report frames the transaction as both a regional acceleration and a funding signal for obesity programs that aim to deliver differentiated pharmacology. Near-term value hinges on demonstrating durable efficacy and tolerability in larger development stages. Separately, a deal item also notes Roche’s positioning around a “promising but competitive” obesity target, reflecting how quickly the obesity field is reorganizing around molecular mechanisms.